Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Assistance Publique - Hôpitaux de Paris
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults patients aged 80 years or less
COVID-19 diagnosis defined as either positive RT-PCR for SARS-CoV-2 or COVID-19 compatible or typical chest CT pattern or positive serology for COVID-19 antibodies
Hypoxemic acute respiratory failure with the following criteria: oxygen saturation level of 92% or less, as measured by pulsed oximetry (SpO2) under oxygen therapy with an oxygen rate of 6L/min or more.
Hospital admission for COVID-19 within 14 days
Patients affiliated
You may not be if
Hypersensitivity to the active substance or to any of the excipients
Pregnancy or breastfeeding woman
Known Hepatic failure (PT \<50%, Factor V \< 50%)
Last known Plasma total bilirubin \> 21 μmol/L
Lactate level \> 4 mmol/L
ALT and AST levels greater than 3 times the upper limit
Pulmonary hypertension (PAPs ≥37 mmHG and/or VmaxIT ≥ 2,9 m/s) or right ventricular dysfunction
History of pulmonary embolism
Diagnosis of pulmonary embolism during the current hospitalization or on-going anticoagulant therapy at curative dose for thromboembolism when hospitalized
PaCO2 \> 45 mmHg
Exacerbation of asthma or chronic respiratory failure
Cardiogenic pulmonary oedema
Systolic blood pressure of 90 mmHg or less, or use of vasopressors
Urgent need for endotracheal intubation at the discretion of the treating physician
Do-not-intubate order or estimated life expectancy less than 6 months
Participation in another interventional research
Clareo Health | Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
